Structure Therapeutics Inc. (GPCR) earnings date
Mar 4, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028" exhibit |
| Q3 FY2026 | "Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies" exhibit |
| Q3 FY2026 | "Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist), demonstrating a ~6-day half-life and no serious adverse events; MAD clinical trial dosing underway, with topline data expected in 1H 2027" exhibit |
| Q3 FY2026 | "Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026 expected to fund projected operations and key clinical milestones through 2028" exhibit |
| Q3 FY2026 | "Topline data are expected in the second half of 2028." exhibit |
| Q2 FY2026 | "Cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026 expected to fund projected operations and key clinical milestones through 2028" exhibit |
| Q2 FY2026 | "As an important component of this strategy, we are advancing ACCG-2671, our potentially first-in-class oral small molecule dual amylin and calcitonin receptor agonist and remain on track to report initial single ascending dose data and initiate a multiple ascending dose clinical trial in the third quarter." exhibit |
| Q2 FY2026 | "Data are expected in Q3 2026." exhibit |
| Q2 FY2026 | "Data are expected in Q4 2026." exhibit |
| Q2 FY2026 | "Data are expected in Q4 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/GPCR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/GPCR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/GPCR/"><img src="https://veritasdata.dev/embed/GPCR.svg" alt="GPCR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/GPCR/)
Script
<script async src="https://veritasdata.dev/embed/GPCR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/GPCR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.